{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T18:03:01Z","timestamp":1784397781744,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,18]]},"DOI":"10.7759\/cureus.112918","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:14:03Z","timestamp":1784394843000},"source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary Function and Radiographic Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review of Rituximab, Interleukin-6 Inhibitors, and Janus Kinase Inhibitors"],"prefix":"10.7759","author":[{"given":"Rohan M","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Chary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Systemic Sclerosis (Scleroderma)","author":"Adigun R","year":"2024","unstructured":"Adigun R, Goyal A, Hariz A. Systemic Sclerosis (Scleroderma). StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683431","article-title":"Systemic sclerosis-associated interstitial lung disease: a comprehensive overview","volume":"40","author":"Mackintosh JA","year":"2019","unstructured":"Mackintosh JA, Stainer A, Barnett JL, Renzoni EA. Systemic sclerosis-associated interstitial lung disease: a comprehensive overview. Semin Respir Crit Care Med. 2019, 40:208-26. 10.1055\/s-0039-1683431","journal-title":"Semin Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S226695","article-title":"Interstitial lung disease in systemic sclerosis: focus on early detection and intervention","volume":"11","author":"Fischer A","year":"2019","unstructured":"Fischer A, Patel NM, Volkmann ER. Interstitial lung disease in systemic sclerosis: focus on early detection and intervention. Open Access Rheumatol. 2019, 11:283-307. 10.2147\/OARRR.S226695","journal-title":"Open Access Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206680","article-title":"The impact of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Mart\u00edn-L\u00f3pez M","year":"2023","unstructured":"Mart\u00edn-L\u00f3pez M, Carreira PE. The impact of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease. J Clin Med. 2023, 12:6680. 10.3390\/jcm12206680","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-19. 10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks: data from a randomized controlled trial","volume":"4","author":"Assassi S","year":"2022","unstructured":"Assassi S, Distler O, Allanore Y, et al.. Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks: data from a randomized controlled trial. ACR Open Rheumatol. 2022, 4:837-44. 10.1002\/acr2.11483","journal-title":"ACR Open Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003426","article-title":"Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review","volume":"9","author":"Petelytska L","year":"2023","unstructured":"Petelytska L, Bonomi F, Cannistr\u00e0 C, et al.. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review. RMD Open. 2023, 9:e003426. 10.1136\/rmdopen-2023-003426","journal-title":"RMD Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020316","article-title":"Therapeutic options for systemic sclerosis: current and future perspectives in tackling immune-mediated fibrosis","volume":"10","author":"Papadimitriou TI","year":"2022","unstructured":"Papadimitriou TI, van Caam A, van der Kraan PM, Thurlings RM. Therapeutic options for systemic sclerosis: current and future perspectives in tackling immune-mediated fibrosis. Biomedicines. 2022, 10:316. 10.3390\/biomedicines10020316","journal-title":"Biomedicines"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/life14020229","article-title":"Targeting progression in pulmonary fibrosis: an overview of underlying mechanisms, molecular biomarkers, and therapeutic intervention","volume":"14","author":"D'Agnano V","year":"2024","unstructured":"D'Agnano V, Mariniello DF, Ruotolo M, et al.. Targeting progression in pulmonary fibrosis: an overview of underlying mechanisms, molecular biomarkers, and therapeutic intervention. Life (Basel). 2024, 14:229. 10.3390\/life14020229","journal-title":"Life (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6340","article-title":"Long-term outcomes after rituximab treatment for patients with systemic sclerosis: follow-up of the DESIRES trial with a focus on serum immunoglobulin levels","volume":"159","author":"Kuzumi A","year":"2023","unstructured":"Kuzumi A, Ebata S, Fukasawa T, et al.. Long-term outcomes after rituximab treatment for patients with systemic sclerosis: follow-up of the DESIRES trial with a focus on serum immunoglobulin levels. JAMA Dermatol. 2023, 159:374-83. 10.1001\/jamadermatol.2022.6340","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher TM","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, et al.. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023, 11:45-54. 10.1016\/S2213-2600(22)00359-9","journal-title":"Lancet Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh D","year":"2021","unstructured":"Roofeh D, Lin CJ, Goldin J, et al.. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2021, 73:1301-10. 10.1002\/art.41668","journal-title":"Arthritis Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna D","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJ, et al.. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018, 77:212-20. 10.1136\/annrheumdis-2017-211682","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/life12122101","article-title":"Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data","volume":"12","author":"Fiorentini E","year":"2022","unstructured":"Fiorentini E, Bonomi F, Peretti S, et al.. Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life (Basel). 2022, 12:2101. 10.3390\/life12122101","journal-title":"Life (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","unstructured":"Effectiveness of targeted immunomodulatory therapies in systemic sclerosis-associated interstitial lung disease. a systematic review. (2026). Accessed: June 15, 2026:  https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261357125."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03654-0","article-title":"Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study","volume":"27","author":"Hiura R","year":"2025","unstructured":"Hiura R, Ayano M, Uchino A, et al.. Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study. Arthritis Res Ther. 2025, 27:193. 10.1186\/s13075-025-03654-0","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103492","article-title":"Evaluation of the mycophenolate mofetil-rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc)","volume":"157","author":"Barde F","year":"2025","unstructured":"Barde F, Chevalier K, Decker P, et al.. Evaluation of the mycophenolate mofetil-rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc). J Autoimmun. 2025, 157:103492. 10.1016\/j.jaut.2025.103492","journal-title":"J Autoimmun"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf006","article-title":"Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis","volume":"64","author":"Goldman NR","year":"2025","unstructured":"Goldman NR, Nihtyanova SI, Beesley CF, et al.. Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis. Rheumatology (Oxford). 2025, 64:SI184-9. 10.1093\/rheumatology\/keaf006","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.014","article-title":"Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database","volume":"84","author":"Yan Q","year":"2025","unstructured":"Yan Q, Bruni C, Garaiman A, et al.. Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Ann Rheum Dis. 2025, 84:620-31. 10.1016\/j.ard.2025.01.014","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103246","article-title":"Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy","volume":"147","author":"Moazedi-Fuerst FC","year":"2024","unstructured":"Moazedi-Fuerst FC, Lackner A, Kreuzer SM, et al.. Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy. J Autoimmun. 2024, 147:103246. 10.1016\/j.jaut.2024.103246","journal-title":"J Autoimmun"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae280","article-title":"Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study","volume":"64","author":"De Luca G","year":"2025","unstructured":"De Luca G, De Lorenzis E, Campochiaro C, et al.. Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study. Rheumatology (Oxford). 2025, 64:1284-91. 10.1093\/rheumatology\/keae280","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead234","article-title":"Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease\u00a0in a clinical trial and long-term observational cohort","volume":"63","author":"Ghuman A","year":"2024","unstructured":"Ghuman A, Khanna D, Lin CJ, et al.. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease\u00a0in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2024, 63:472-81. 10.1093\/rheumatology\/kead234","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06660-2","article-title":"Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease","volume":"42","author":"Junfei Z","year":"2023","unstructured":"Junfei Z, Meihua G, Shuai Z, et al.. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2023, 42:2823-32. 10.1007\/s10067-023-06660-2","journal-title":"Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.55730\/1300-0144.5739","article-title":"Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis","volume":"53","author":"Yal\u00e7inkaya Y","year":"2023","unstructured":"Yal\u00e7inkaya Y, Artim Esen B, Amikishiyev S, Aliyeva N, G\u00fcl A, \u00d6cal L, Inan\u00e7 M. Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. Turk J Med Sci. 2023, 53:1704-12. 10.55730\/1300-0144.5739","journal-title":"Turk J Med Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"Kuster S","year":"2022","unstructured":"Kuster S, Jordan S, Elhai M, et al.. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022, 8:e002477. 10.1136\/rmdopen-2022-002477","journal-title":"RMD Open"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac136","article-title":"Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan","volume":"61","author":"Isomura Y","year":"2022","unstructured":"Isomura Y, Shirai Y, Kuwana M. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology (Oxford). 2022, 61:4491-6. 10.1093\/rheumatology\/keac136","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna D","year":"2022","unstructured":"Khanna D, Lin CJ, Furst DE, et al.. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022, 205:674-84. 10.1164\/rccm.202103-0714OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05785-6","article-title":"Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study","volume":"40","author":"Y\u0131lmaz DD","year":"2021","unstructured":"Y\u0131lmaz DD, Borekci S, Musellim B. Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. Clin Rheumatol. 2021, 40:4071-9. 10.1007\/s10067-021-05785-6","journal-title":"Clin Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04545-0","article-title":"Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data","volume":"40","author":"Robles-Perez A","year":"2020","unstructured":"Robles-Perez A, Dorca J, Castellv\u00ed I, Nolla JM, Molina-Molina M, Narv\u00e1ez J. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data. Rheumatol Int. 2020, 40:719-26. 10.1007\/s00296-020-04545-0","journal-title":"Rheumatol Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar G","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018, 57:2106-13. 10.1093\/rheumatology\/key213","journal-title":"Rheumatology (Oxford)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis D","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al.. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017, 46:625-31. 10.1016\/j.semarthrit.2016.10.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref33","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"100","author":"Lepri G","year":"2016","unstructured":"Lepri G, Avouac J, Air\u00f2 P, et al.. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016, 100:181-85.","journal-title":"Clin Exp Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan S","year":"2015","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015, 74:1188-94. 10.1136\/annrheumdis-2013-204522","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna D","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al.. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016, 387:2630-40. 10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road068","article-title":"Efficacy and\u00a0safety of\u00a0tocilizumab in\u00a0Japanese patients with systemic sclerosis and\u00a0associated interstitial lung disease: a subgroup analysis of\u00a0a global, randomised, controlled Phase 3 trial","volume":"34","author":"Kuwana M","year":"2024","unstructured":"Kuwana M, Takehara K, Tanaka Y, Yamashita K, Katsumata K, Takata M, Shima Y. Efficacy and\u00a0safety of\u00a0tocilizumab in\u00a0Japanese patients with systemic sclerosis and\u00a0associated interstitial lung disease: a subgroup analysis of\u00a0a global, randomised, controlled Phase 3 trial. Mod Rheumatol. 2024, 34:530-40. 10.1093\/mr\/road068","journal-title":"Mod Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/publications14010004","article-title":"The Newcastle-Ottawa scale for assessing the quality of studies in systematic reviews","volume":"14","author":"Gualdi-Russo E","year":"2026","unstructured":"Gualdi-Russo E, Zaccagni L. The Newcastle-Ottawa scale for assessing the quality of studies in systematic reviews. Publications. 2026, 14:4. 10.3390\/publications14010004","journal-title":"Publications"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0259-2024","article-title":"A new era in the treatment of progressive fibrosing interstitial lung diseases","volume":"21","author":"Denis A","year":"2025","unstructured":"Denis A, Tsiri P, Guiot J, Tzouvelekis A. A new era in the treatment of progressive fibrosing interstitial lung diseases. Breathe (Sheff). 2025, 21:240259. 10.1183\/20734735.0259-2024","journal-title":"Breathe (Sheff)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter M","year":"2023","unstructured":"Kreuter M, Hoffmann-Vold AM, Matucci-Cerinic M, et al.. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2023, 62:SI43-53. 10.1093\/rheumatology\/keac325","journal-title":"Rheumatology (Oxford)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15172243","article-title":"Diagnostics, efficacy, and safety of immunomodulatory and anti-fibrotic treatment for interstitial lung disease associated with systemic scleroderma (SSc-ILD)","volume":"15","author":"Piecuch D","year":"2025","unstructured":"Piecuch D, Hanczyk E, Zemsta K, Zwoli\u0144ski M, Kopcia\u0142 S, Jo\u0144ska J. Diagnostics, efficacy, and safety of immunomodulatory and anti-fibrotic treatment for interstitial lung disease associated with systemic scleroderma (SSc-ILD). Diagnostics (Basel). 2025, 15:2243. 10.3390\/diagnostics15172243","journal-title":"Diagnostics (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/art.43326","article-title":"Case-based immunology: B cells and systemic sclerosis interstitial lung disease","volume":"78","author":"Goldman N","year":"2026","unstructured":"Goldman N, Ong V, Denton CP. Case-based immunology: B cells and systemic sclerosis interstitial lung disease. Arthritis Rheumatol. 2026, 78:566-81. 10.1002\/art.43326","journal-title":"Arthritis Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja S","year":"2018","unstructured":"Kafaja S, Clements PJ, Wilhalme H, et al.. Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2018, 197:644-52. 10.1164\/rccm.201709-1845OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref44","article-title":"Diffusing capacity of the lungs for carbon monoxide","author":"Goldin J","year":"2024","unstructured":"Goldin J, Cascella M. Diffusing capacity of the lungs for carbon monoxide. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510282-pulmonary-function-and-radiographic-outcomes-in-systemic-sclerosis-associated-interstitial-lung-disease-a-systematic-review-of-rituximab-interleukin-6-inhibitors-and-janus-kinase-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:14:04Z","timestamp":1784394844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510282-pulmonary-function-and-radiographic-outcomes-in-systemic-sclerosis-associated-interstitial-lung-disease-a-systematic-review-of-rituximab-interleukin-6-inhibitors-and-janus-kinase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.112918","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}